These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 9188616)

  • 21. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients.
    Vergne L; Peeters M; Mpoudi-Ngole E; Bourgeois A; Liegeois F; Toure-Kane C; Mboup S; Mulanga-Kabeya C; Saman E; Jourdan J; Reynes J; Delaporte E
    J Clin Microbiol; 2000 Nov; 38(11):3919-25. PubMed ID: 11060045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine.
    García-Lerma JG; Nidtha S; Heneine W
    J Infect Dis; 2001 Aug; 184(4):507-10. PubMed ID: 11471110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A genetic analysis of HIV-1 from Punjab, India reveals the presence of multiple variants.
    Jameel S; Zafrullah M; Ahmad M; Kapoor GS; Sehgal S
    AIDS; 1995 Jul; 9(7):685-90. PubMed ID: 7546411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV type 1 pol gene diversity and archived nevirapine resistance mutation in pregnant women in Rwanda.
    Servais J; Lambert C; Karita E; Vanhove D; Fischer A; Baurith T; Schmit JC; Schneider F; Hemmer R; Arendt V
    AIDS Res Hum Retroviruses; 2004 Mar; 20(3):279-83. PubMed ID: 15117451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An association between HIV-1 subtypes and mode of transmission in Cape Town, South Africa.
    van Harmelen J; Wood R; Lambrick M; Rybicki EP; Williamson AL; Williamson C
    AIDS; 1997 Jan; 11(1):81-7. PubMed ID: 9110079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Heteroduplex mobility assay and phylogenetic analysis of V3 region sequences of human immunodeficiency virus type 1 isolates from Gulu, northern Uganda. The Italian-Ugandan Cooperation AIDS Program.
    Buonaguro L; Del Guadio E; Monaco M; Greco D; Corti P; Beth-Giraldo E; Buonaguro FM; Giraldo G
    J Virol; 1995 Dec; 69(12):7971-81. PubMed ID: 7494310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin.
    Gao F; Robertson DL; Morrison SG; Hui H; Craig S; Decker J; Fultz PN; Girard M; Shaw GM; Hahn BH; Sharp PM
    J Virol; 1996 Oct; 70(10):7013-29. PubMed ID: 8794346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of the reverse transcriptase of a human immunodeficiency virus type 1 group O isolate.
    Quiñones-Mateu ME; Soriano V; Domingo E; Menéndez-Arias L
    Virology; 1997 Sep; 236(2):364-73. PubMed ID: 9325244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.
    Demeter LM; Meehan PM; Morse G; Gerondelis P; Dexter A; Berrios L; Cox S; Freimuth W; Reichman RC
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Feb; 14(2):136-44. PubMed ID: 9052722
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical data sets of human immunodeficiency virus type 1 reverse transcriptase-resistant mutants explained by a mathematical model.
    Stilianakis NI; Boucher CA; De Jong MD; Van Leeuwen R; Schuurman R; De Boer RJ
    J Virol; 1997 Jan; 71(1):161-8. PubMed ID: 8985335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
    Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
    Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs.
    de Jong JJ; Goudsmit J; Lukashov VV; Hillebrand ME; Baan E; Huismans R; Danner SA; ten Veen JH; de Wolf F; Jurriaans S
    AIDS; 1999 Jan; 13(1):75-80. PubMed ID: 10207547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy.
    Kuritzkes DR; Shugarts D; Bakhtiari M; Poticha D; Johnson J; Rubin M; Gingeras TR; Kennedy M; Eron JJ
    J Acquir Immune Defic Syndr; 2000 Jan; 23(1):26-34. PubMed ID: 10708053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid.
    Briones C; Pérez-Olmeda M; Rodríguez C; del Romero J; Hertogs K; Soriano V
    J Acquir Immune Defic Syndr; 2001 Feb; 26(2):145-50. PubMed ID: 11242181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
    Rusconi S; La Seta Catamancio S; Sheridan F; Parker D
    J Clin Virol; 2000 Dec; 19(3):135-42. PubMed ID: 11090748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.
    Picard V; Angelini E; Maillard A; Race E; Clavel F; Chêne G; Ferchal F; Molina JM
    J Infect Dis; 2001 Sep; 184(6):781-4. PubMed ID: 11517441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors.
    Loya S; Bakhanashvili M; Tal R; Hughes SH; Boyer PL; Hizi A
    AIDS Res Hum Retroviruses; 1994 Aug; 10(8):939-46. PubMed ID: 7529032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine.
    Stoeckli TC; MaWhinney S; Uy J; Duan C; Lu J; Shugarts D; Kuritzkes DR
    Antimicrob Agents Chemother; 2002 Dec; 46(12):4000-3. PubMed ID: 12435711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A survey of synthetic HIV-1 peptides with natural and chimeric sequences for differential reactivity with Zimbabwean, Tanzanian and Swedish HIV-1-positive sera.
    Blomberg J; Lawoko A; Pipkorn R; Moyo S; Malmvall BE; Shao J; Dash R; Tswana S
    AIDS; 1993 Jun; 7(6):759-67. PubMed ID: 8363754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.